🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "huge turning point" in the fight against drug-resistant strains of the pathogen, according to health experts.

An International Challenge

The sexually transmitted infection are escalating around the world, with data suggesting in excess of 82 million infections annually. Notably increased rates are observed in Africa and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary step in the face of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce available drugs at this time.”

Health officials are increasingly worried about the surge in treatment-resistant strains. The WHO has listed it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Drugs Gain Clearance

One new antibiotic, marketed under the name Nuzolvence, was authorized by the US FDA in mid-December for combating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Scientists believe that specific application of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the drugmaker GSK, also received approval in the same week. This drug, which is employed against urinary tract infections, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to develop it.

“This authorization marks a significant shift in the therapy of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Outcomes and Worldwide Availability

As per data published in a prominent scientific publication, the new drug cured over nine in ten of uncomplicated infections. This establishes an equal footing with the typical regimen, which combines an injection and a pill. The research involved nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the ability to license and sell the drug in a wide range of regions with limited resources.

Doctors treating patients have shared hope. The availability of a one-pill regimen like this is described as a "game-changer" for gonorrhoea control. This is deemed vital to lessen the impact of the disease for individuals and to stop the proliferation of extremely resistant gonorrhoea globally.